During premarket
trading
hours,
there
were
many
stocks
that
continued
to
break
up
to
the
upside.These
stocks
are
usually
going
up
or
down
on
with
news.If
you
are
looking
to
day
trade
today,
you
might
want
to
check
out
the
following
stocks. I
usually
throw
these
on
my
watch
list
and
monitor
with
resistance
&
support
levels.
Below
are a
list
of
stocks
that I
am
watching
for
today.You can also check previous stocks to buy reports- Right Here
Premarket Gainers / Losers
Top #PreMarket Gainers
Sears Holdings (NASDAQ: SHLD shares rose 25.47% to $40.99 in
pre-market trading after the company said it is actively exploring REIT
transaction involving 200 to 300 owned properties through a rights offering to
holdings shareholders.
Rockwell Medical (NASDAQ: RMTI)
shares surged 23.26% to $11.50 in pre-market trading as the FDA Oncologic Drugs
Advisory Committee voted in favor of Triferic 8 to 3.
Zynga (NASDAQ: ZNGA) shares gained 9.32% to $2.58 in the
pre-market trading session after the company beat Q3 revenue expectations and
posted a loss in line with Wall Street's views. Analysts at Needham
upgraded Zynga from Hold to Buy.
Alpha Pro Tech (NYSE: APT
shares jumped 8.44% to $3.34 in pre-market trading after the company reported a
substantial rise in its October orders.
Top #PreMarket Losers:
Salix Pharmaceuticals (NASDAQ: SLXP) shares slipped 33.79%
to $91.74 in pre-market trading after the company reported downbeat Q3 results
and appointed Timothy Creech as CFO. Analysts at Stifel Nicolaus downgraded
Salix Pharma from Buy to Hold and removed the price target of $189.
Performant Financial (NASDAQ: PFMT fell 18.96% to $7.01 in
pre-market trading after the company reported downbeat Q3 results and lowered
its FY14 revenue forecast. William Blair downgraded Performant Financial from
Outperform to Market Perform.
Intercept Pharmaceuticals (NASDAQ: ICPT
shares declined 14.97% to $210.00 in pre-market trading after the company
reported a Q3 loss of $1.69 per share and announced that results from the FLINT
trial in nonalcoholic steatohepatitis (NASH) were published in The Lancet.
Ubiquiti Networks (NASDAQ: UBNT)
shares dropped 14.79% to $29.50 in pre-market trading after the company
reported weaker-than-expected FQ1 results and issued a downbeat Q2 outlook.
Wunderlich lowered the price target on Ubiquiti Networks from $55.00 to $50.00.
